ai company addressing drug development exscientia simply not game long generated new candidates late stage trials process typically takes years hopkins claims candidates exscientia identified reach human trials early year end day judged drugs deliver says finding molecule hit new target not major challenge drug discovery need identify targets place spot proteins roles diseases biopharma company berg applies ai sift information derived human tissue samples approach aims solve problems hang research drug targets according berg ceo niven r. narain efforts tend based researcher theory hunch bias results overly restrict pool candidates turn targets correlated disease not ultimately prove causative means